Advances in multimodality therapy for hepatocellular carcinoma
DOI:10.3969/j.issn.1001-5256.2020.10.004
- VernacularTitle:肝细胞癌综合治疗进展
- Author:
Yizhen FU
1
;
Li XU
Author Information
1. Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(10):2179-2183
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer is one of the most common malignances worldwide, among which hepatocellular carcinoma (HCC) accounts for about 90% of all cases. Multidisciplinary multimodality therapy involving surgery, ablation, interventional treatment, targeted therapy, and immunotherapy is an effective strategy for the treatment of liver cancer. In recent years, great achievements have been made in multimodality therapy for liver cancer, especially the advances in combination therapy for advanced liver cancer and drug research and development, which improves the overall prognosis of liver cancer patients, and the improvement in targeted drug therapy and immunotherapy is expected to change the pattern of multimodality therapy for liver cancer. This article systematically reviews the recent advances in multimodality therapy for liver cancer from the aspects of local treatment and systemic therapy.
